Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Albain KS, Paik S, van't Veer L.

Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5. Review.

PMID:
19914534
2.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, Jönsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
3.

Adjuvant therapy for breast cancer.

[No authors listed]

NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. Review.

PMID:
11512506
4.

[Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].

Mauriac L, Blanc-Vincent MP, Luporsi E, Cutuli B, Fourquet A, Garbay JR, Giard S, Spyratos F, Zafrani B, Dilhuydy JM.

Bull Cancer. 2000 Jun;87(6):469-90. Review. French.

5.

Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.

Dobbe E, Gurney K, Kiekow S, Lafferty JS, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 1;65(1):23-8. Review.

PMID:
18159035
6.

Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.

Ross JS.

Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf. Review.

PMID:
19546609
9.

National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.

National Institutes of Health Consensus Development Panel.

J Natl Cancer Inst Monogr. 2001;(30):5-15. Review.

PMID:
11773285
10.

Genomics of adjuvant therapy for breast cancer.

Kim SR, Paik S.

Cancer J. 2011 Nov-Dec;17(6):500-4. doi: 10.1097/PPO.0b013e31823e5370. Review.

PMID:
22157294
11.
12.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
13.

Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.

Monnier A.

Expert Rev Anticancer Ther. 2006 Oct;6(10):1355-9. Review.

PMID:
17069521
14.

Adjuvant therapy for breast cancer.

Hennessy BT, Pusztai L.

Minerva Ginecol. 2005 Jun;57(3):305-26. Review.

PMID:
16166938
15.

Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.

Colleoni M, Viale G, Goldhirsch A.

Breast. 2009 Oct;18 Suppl 3:S137-40. doi: 10.1016/S0960-9776(09)70289-9. Review.

PMID:
19914533
16.

High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors.

McGuire WP.

Curr Probl Cancer. 1998 May-Jun;22(3):135-77. Review.

PMID:
9659570
17.

Is gene array testing to be considered routine now?

Paik S.

Breast. 2011 Oct;20 Suppl 3:S87-91. doi: 10.1016/S0960-9776(11)70301-0. Review.

PMID:
22015300
18.

Adjuvant chemotherapy in the node-negative breast cancer patient.

Styblo TM, Wood WC.

Surg Clin North Am. 1996 Apr;76(2):327-41. Review.

PMID:
8610267
19.

Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.

Hornberger J, Alvarado MD, Rebecca C, Gutierrez HR, Yu TM, Gradishar WJ.

J Natl Cancer Inst. 2012 Jul 18;104(14):1068-79. doi: 10.1093/jnci/djs261. Epub 2012 Jul 5. Review.

PMID:
22767204
20.

Adjuvant chemotherapy in luminal breast cancers.

Lim E, Winer EP.

Breast. 2011 Oct;20 Suppl 3:S128-31. doi: 10.1016/S0960-9776(11)70309-5. Review.

PMID:
22015279

Supplemental Content

Support Center